Delay to filings for Eisai's sepsis drug eritoran
This article was originally published in Scrip
Executive Summary
Eisai's hopes of filing its sepsis treatment eritoran (E5564) early have been dashed after an independent drug monitoring committee (DMC) recommended that it enrol the full 2,000 patients in its Phase III ACCESS trial, rather than stopping at the 1,500 patients enrolled so far.